Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)

With the introduction of the latest class of biologic drugs targeting interleukin (IL)-23p19, three new, highly effective drugs can be used for the treatment of chronic plaque psoriasis. However, poorer skin improvement as well as higher rates of serious adverse events have been reported for patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Graier, T., Weger, W., Jonak, C., Sator, P., Zikeli, C., Prillinger, K., Sassmann, C., Gruber, B., Saxinger, W., Ratzinger, G., Painsi, C., Mlynek, A., Häring, N., Sadoghi, B., Trattner, H., Müllegger, R., Quehenberger, F., Salmhofer, W., Wolf, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442573/
https://www.ncbi.nlm.nih.gov/pubmed/36064563
http://dx.doi.org/10.1038/s41598-022-18790-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442573/
https://www.ncbi.nlm.nih.gov/pubmed/36064563
http://dx.doi.org/10.1038/s41598-022-18790-9

Ejemplares similares